Equillium Announces Common Stock Purchase Agreement for up to?$15 Million with Lincoln Park Capital

LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, today announced it has entered into a common stock purchase agreement for up to $15 million with?Lincoln Park Capital Fund, LLC (?LPC?), a?Chicago-based institutional investor.?